The MajesTEC-7 clinical research study
Learn about this study for adults with newly diagnosed multiple myeloma.
The MajesTEC-7 clinical research study
Learn about this study for adults with newly diagnosed multiple myeloma.
This study is for adults with newly diagnosed multiple myeloma who are either unable to receive a stem cell transplant or are not receiving one as initial therapy.
You can join the study if:
- Are 18 years of age or older
- Have been newly diagnosed with multiple myeloma
- Are not receiving a stem cell transplant as initial therapy
Additional eligibility criteria will apply.
You cannot join the study if:
- Have received any prior therapy for multiple myeloma or smoldering myeloma other than a short course of corticosteroids
- Have had plasmapheresis (plasma exchange) in the last 28 days
- Have had a stroke, transient ischemic attack, or seizure in the last 6 months
Additional eligibility criteria will apply.
The study is divided into 3 parts: Screening, the Study Treatment Period, and the Follow-Up Period.
During Screening, the study doctor will determine if you are eligible to join the study.
If you are eligible and agree to join, you will begin the Study Treatment Period. In this period, you will be randomly assigned (like drawing numbers out of a hat) to 1 of 3 groups:
- Group A: Receives one of the investigational medications + standard multiple myeloma medications
- Group B: Receives the other investigational medication + standard multiple myeloma medications
- Group C: Receives standard multiple myeloma medications only
There is an equal chance of being in any of the 3 groups, and you will know which group you are in.
You will receive your study medications (investigational and/or standard) during repeating 28-day cycles. You can continue in the study as long as you are responding to your study medication and do not experience side effects that prevent you from taking it.
You will have regular visits with the study doctor/staff. These visits will become less frequent as you continue in the study.
When you stop receiving study medication, you will begin the Follow-Up Period. In this period, you will have regular visits with the study doctor/staff until the study ends. These visits will help the study doctor/staff determine the long-term effects of your study medication.
Research studies allow doctors and researchers to evaluate investigational medications. When you participate in a research study, you may help them learn more about the safety and efficacy of investigational medications.
Your participation may help advance research for multiple myeloma.
See if you may qualify
Answer the following questions to see if you or someone you know may be eligible to take part in this study.
Please keep in mind: Even if you believe you meet the eligibility criteria, joining a clinical research study is not guaranteed. Whether you’re referred or able to take part depends on a review by a qualified healthcare professional. This questionnaire is intended for United States participants only.
Note about privacy: Email responses may not be encrypted. This means there’s a chance the messages could be seen by someone other than the intended recipient. We will avoid including sensitive personal information in emails whenever possible. However, we cannot guarantee that no sensitive information will be revealed indirectly.
About your information:
With your consent, we will use your answers to help determine whether you may be eligible for this clinical trial. You can withdraw your consent at any time.
Your information may be transferred to countries outside your country of residence, including the United States, which may have different data protection rules.
If you submit any personal information about someone else, you confirm that you have permission to do so.
Please read our Privacy policy for more details.